- Home
- WLAC vs PLX Comparison
WLAC vs PLX Comparison
Compare WLAC & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLAC
- PLX
- Stock Information
- Founded
- WLAC 2024
- PLX 1993
- Country
- WLAC United States
- PLX United States
- Employees
- WLAC N/A
- PLX N/A
- Industry
- WLAC
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WLAC
- PLX Health Care
- Exchange
- WLAC Nasdaq
- PLX Nasdaq
- Market Cap
- WLAC 215.3M
- PLX 204.9M
- IPO Year
- WLAC 2024
- PLX 1998
- Fundamental
- Price
- WLAC $12.63
- PLX $2.15
- Analyst Decision
- WLAC
- PLX Strong Buy
- Analyst Count
- WLAC 0
- PLX 1
- Target Price
- WLAC N/A
- PLX $15.00
- AVG Volume (30 Days)
- WLAC 923.3K
- PLX 1.1M
- Earning Date
- WLAC 01-01-0001
- PLX 11-13-2025
- Dividend Yield
- WLAC N/A
- PLX N/A
- EPS Growth
- WLAC N/A
- PLX N/A
- EPS
- WLAC N/A
- PLX 0.08
- Revenue
- WLAC N/A
- PLX $61,948,000.00
- Revenue This Year
- WLAC N/A
- PLX $14.53
- Revenue Next Year
- WLAC N/A
- PLX $75.77
- P/E Ratio
- WLAC $933.68
- PLX $24.02
- Revenue Growth
- WLAC N/A
- PLX 62.79
- 52 Week Low
- WLAC $9.80
- PLX $1.01
- 52 Week High
- WLAC $15.19
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- WLAC N/A
- PLX 48.79
- Support Level
- WLAC N/A
- PLX $1.60
- Resistance Level
- WLAC N/A
- PLX $2.55
- Average True Range (ATR)
- WLAC 0.00
- PLX 0.16
- MACD
- WLAC 0.00
- PLX -0.06
- Stochastic Oscillator
- WLAC 0.00
- PLX 51.18
About WLAC Willow Lane Acquisition Corp. Class A Ordinary Shares
Willow Lane Acquisition Corp is a blank check company.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.